Testing Experimental Medication in Healthy Subjects
common.study.values.description
“A Study of LY3502970 in Healthy Participants”
The main purposes of this study are to determine: - The safety of LY3502970 and any side effects that might be associated with it. - How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it. This study has 4 parts (A, B, C, and D). Parts A and D involve a single dose of LY3502970 and will last about 15 days. Part B involves multiple doses of LY3502970 and will last about 4 weeks. Part C involves two single doses of LY3502970 and will last about 29 days. Each participant will enroll in only one part. Screening must be completed within 28 days before study start. This study is for research purposes only, and is not intended to treat any medical condition.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Drug - LY3502970
Administered orally.
Drug - Placebo
Administered orally.
Drug - Atorvastatin
Administered orally.
Drug - Simvastatin
Administered orally.
Drug - Midazolam
Administered orally.
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Healthy Subjects
common.study.values.clinical-trial-id
NCT03929744
participant.views.study.view.id
eVO9oa
